A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
- Author
- KANAI, Masashi1 ; YOSHIMURA, Kenichi2 ; YANAGIHARA, Kazuhiro1 ; YAZUMI, Shujiro3 ; CHIBA, Tsutomu1 6 ; GUHA, Sushovan7 ; AGGARWAL, Bharat B8 ; ASADA, Masanori3 ; IMAIZUMI, Atsushi4 ; SUZUKI, Chihiro2 ; MATSUMOTO, Shigemi1 ; NISHIMURA, Takafumi1 ; MORI, Yukiko1 ; MASUI, Toshihiko5 ; KAWAGUCHI, Yoshiya5
[1] Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
[2] Translational Research Center, Kyoto University Hospital, Kyoto, Japan
[3] Kitano Hospital, Osaka, Japan
[4] Theravalues Corporation, Tokyo, Japan
[5] Department of Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan
[6] Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan
[7] Department of Gastrointestinal Medicine and Nutrition, MD Anderson Cancer Center, Houston, TX, United States
[8] Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, United States - Source
Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 1, pp 157-164, 8 p ; ref : 29 ref
- CODEN
- CCPHDZ
- ISSN
- 0344-5704
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Curcumin Gemcitabine Pancreatic cancer
- Keyword (fr)
- Anticancéreux Cancer du pancréas Chimiothérapie Curcumine Essai clinique phase I Essai clinique phase II Gemcitabine Homme Malade Polyphénol Résistance Traitement Antimétabolite Cancer Dérivé de la pyrimidine Fluor Composé organique Inhibiteur de la tyrosine kinase Pathologie de l'appareil digestif Pathologie du pancréas Phénols Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Antineoplastic agent Pancreas cancer Chemotherapy Curcumin Phase I trial Phase II trial Gemcitabine Human Patient Polyphenol Resistance Treatment Antimetabolic Cancer Pyrimidine derivatives Fluorine Organic compounds Tyrosine kinase inhibitor Digestive diseases Pancreatic disease Phenols Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del páncreas Quimioterapia Curcumina Ensayo clínico fase I Ensayo clínico fase II Gemcitabina Hombre Enfermo Polifenol Resistencia Tratamiento Antimetabólito Cáncer Pirimidina derivado Fluor Compuesto orgánico Inhibidor tyrosine kinase Aparato digestivo patología Páncreas patología Fenoles Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24306306
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00280-010-1470-2 
https://dx.doi.org/10.1007/s00280-010-1470-2
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"68\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"157\";s:8:\"\u0000*\u0000epage\";s:3:\"164\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"YOSHIMURA, Kenichi\";i:1;s:20:\"YANAGIHARA, Kazuhiro\";i:2;s:15:\"YAZUMI, Shujiro\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"GUHA, Sushovan\";i:5;s:18:\"AGGARWAL, Bharat B\";i:6;s:15:\"ASADA, Masanori\";i:7;s:17:\"IMAIZUMI, Atsushi\";i:8;s:15:\"SUZUKI, Chihiro\";i:9;s:18:\"MATSUMOTO, Shigemi\";i:10;s:19:\"NISHIMURA, Takafumi\";i:11;s:12:\"MORI, Yukiko\";i:12;s:16:\"MASUI, Toshihiko\";i:13;s:18:\"KAWAGUCHI, Yoshiya\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"68\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"157\";s:8:\"\u0000*\u0000epage\";s:3:\"164\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"YOSHIMURA, Kenichi\";i:1;s:20:\"YANAGIHARA, Kazuhiro\";i:2;s:15:\"YAZUMI, Shujiro\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"GUHA, Sushovan\";i:5;s:18:\"AGGARWAL, Bharat B\";i:6;s:15:\"ASADA, Masanori\";i:7;s:17:\"IMAIZUMI, Atsushi\";i:8;s:15:\"SUZUKI, Chihiro\";i:9;s:18:\"MATSUMOTO, Shigemi\";i:10;s:19:\"NISHIMURA, Takafumi\";i:11;s:12:\"MORI, Yukiko\";i:12;s:16:\"MASUI, Toshihiko\";i:13;s:18:\"KAWAGUCHI, Yoshiya\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"68\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"157\";s:8:\"\u0000*\u0000epage\";s:3:\"164\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"YOSHIMURA, Kenichi\";i:1;s:20:\"YANAGIHARA, Kazuhiro\";i:2;s:15:\"YAZUMI, Shujiro\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"GUHA, Sushovan\";i:5;s:18:\"AGGARWAL, Bharat B\";i:6;s:15:\"ASADA, Masanori\";i:7;s:17:\"IMAIZUMI, Atsushi\";i:8;s:15:\"SUZUKI, Chihiro\";i:9;s:18:\"MATSUMOTO, Shigemi\";i:10;s:19:\"NISHIMURA, Takafumi\";i:11;s:12:\"MORI, Yukiko\";i:12;s:16:\"MASUI, Toshihiko\";i:13;s:18:\"KAWAGUCHI, Yoshiya\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"68\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"157\";s:8:\"\u0000*\u0000epage\";s:3:\"164\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"YOSHIMURA, Kenichi\";i:1;s:20:\"YANAGIHARA, Kazuhiro\";i:2;s:15:\"YAZUMI, Shujiro\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"GUHA, Sushovan\";i:5;s:18:\"AGGARWAL, Bharat B\";i:6;s:15:\"ASADA, Masanori\";i:7;s:17:\"IMAIZUMI, Atsushi\";i:8;s:15:\"SUZUKI, Chihiro\";i:9;s:18:\"MATSUMOTO, Shigemi\";i:10;s:19:\"NISHIMURA, Takafumi\";i:11;s:12:\"MORI, Yukiko\";i:12;s:16:\"MASUI, Toshihiko\";i:13;s:18:\"KAWAGUCHI, Yoshiya\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-010-1470-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"68\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"157\";s:8:\"\u0000*\u0000epage\";s:3:\"164\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"KANAI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Masashi\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:18:\"YOSHIMURA, Kenichi\";i:1;s:20:\"YANAGIHARA, Kazuhiro\";i:2;s:15:\"YAZUMI, Shujiro\";i:3;s:14:\"CHIBA, Tsutomu\";i:4;s:14:\"GUHA, Sushovan\";i:5;s:18:\"AGGARWAL, Bharat B\";i:6;s:15:\"ASADA, Masanori\";i:7;s:17:\"IMAIZUMI, Atsushi\";i:8;s:15:\"SUZUKI, Chihiro\";i:9;s:18:\"MATSUMOTO, Shigemi\";i:10;s:19:\"NISHIMURA, Takafumi\";i:11;s:12:\"MORI, Yukiko\";i:12;s:16:\"MASUI, Toshihiko\";i:13;s:18:\"KAWAGUCHI, Yoshiya\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:124:\"A phase I\/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
